SEC Form 4 · accession 0001562180-15-001102
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jodie Pope Morrison
Officer — President and CEO · Director
Period of report
Dec 15, 2015
Accepted (ET)
Dec 17, 2015 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.65 | Dec 15, 2015 | A | 189,000 | A | — | Dec 14, 2025 | Common Stock | 189,000 | 189,000 | D |
Explanation of responses
- F1This option vests with respect to 12.5% of the shares underlying the option vesting on June 30, 2016 and an additional 2.0833% on the last day of each month thereafter through December 31, 2019.